Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Trading 11-26 10:55:22 EST

395.77

-11.76

-2.89%

High408.67	Low393.79	Vol7.39M
Open406.91	D1 Closing407.53	Amplitude3.65%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O43.43M	T/O Rate--	Tradable Shares0.00
P/B2.100844	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":395.76993,"timestamp":1732636519755,"preClose":407.5339,"halted":0,"volume":7391812,"delay":0,"changeRate":-0.028866,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-11.763977,"latestTime":"11-26 10:55:22 EST","open":406.91272,"high":408.67166,"low":393.79422,"amount":43426244.562028,"amplitude":0.036506,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1732654800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.100844,"peRate":-5.311048,"turnoverRate":0.010158,"increases":1,"decrements":5,"flats":0,"marketCap":8435749056,"floatMarketCap":7956482600},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2486734670","title":"Promising Outlook for Intellia Therapeutics’ Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2486734670","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486734670?lang=en_us&edition=fundamental","pubTime":"2024-11-26 19:17","pubTimestamp":1732619824,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-outlook-for-intellia-therapeutics-nex-z-in-attr-cm-treatment-backed-by-safety-and-patient-interest?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CM","LU1861558580.USD","BK4139","BK4585","NTLA","BK4535","BK4556","LU1861559042.SGD","BK4588","BK4207"],"gpt_icon":0},{"id":"2486056963","title":"Sector Update: Health Care Stocks Rise in Monday Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2486056963","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486056963?lang=en_us&edition=fundamental","pubTime":"2024-11-26 02:45","pubTimestamp":1732560320,"startTime":"0","endTime":"0","summary":"Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.6% and the Health Care Select Sector SPDR Fund (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) climbed 1","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BBIO","BK4585","BK4007","BK4581","IBB","LU1861559042.SGD","SAVA","BK4535","NTLA","XLV","BK4588","BK4556","LU1861558580.USD","BK4547","BK4139"],"gpt_icon":1},{"id":"2486386031","title":"Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2486386031","media":"MT Newswires Live","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486386031?lang=en_us&edition=fundamental","pubTime":"2024-11-26 00:02","pubTimestamp":1732550534,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics  said Monday that the US Food and Drug Administration has granted regenerative medicine advanced therapy designation to nexiguran ziclumeran for the treatment of hereditary transthyretin amyloidosis with polyneuropathy.The development and commercialization of the therapy, also called nex-z and NTLA-2001, is being led by Intellia as part of a multi-target deal with Regeneron , the company added.Nex-z is a \"clustered regularly interspaced short palindromic repeats,\" or CRISPR-based investigational therapy designed to stop the production of the transthyretin protein with a single dose, the company said.The FDA designation is meant to speed up the development and review of promising treatments, including gene therapies, for serious or life-threatening diseases. This designation offers benefits such as early discussions with the FDA, the potential for faster approval, and priority review for the product's biologics license application.Shares of Intellia Therapeutics ro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0058720904.USD","LU2023250504.SGD","BK4157","IE00B19Z4B17.USD","LU0289739699.SGD","LU0109394709.USD","BK6522","LU0114720955.EUR","LU2089984988.USD","LU0882574055.USD","LU2362541273.HKD","BK4556","NTLA","LU0053666078.USD","LU2362541513.USD","BK4585","BK4535","AEIS","IE00B7SZL793.SGD","LU1974910355.USD","LU0889565916.HKD","BLZ.SI","LU1861559042.SGD","LU0823416689.USD","BK4588","IE00B66KJ199.SGD","LU0320765992.SGD","LU2362540622.SGD","BK4139","IE0031619046.USD","REGN","LU1917777945.USD","LU2106854487.HKD","BK6088","LU2468319806.SGD","LU1861558580.USD"],"gpt_icon":0},{"id":"2486608548","title":"BRIEF-Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To Nexiguran Ziclumeran","url":"https://stock-news.laohu8.com/highlight/detail?id=2486608548","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486608548?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:41","pubTimestamp":1732538518,"startTime":"0","endTime":"0","summary":"BRIEF-Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To Nexiguran ZiclumeranNov 25 (Reuters) - Intellia Therapeutics Inc NTLA.O:INTELLIA THERAPEUTICS AN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUABNPX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU1861558580.USD","BK4139","BK4556","BK4535","NTLA","BK4585","BK4588"],"gpt_icon":0},{"id":"2486088083","title":"Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486088083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486088083?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:30","pubTimestamp":1732537801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241125:nTUABNPX7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","NTLA","BK4588","BK4139","BK4556","BK4585","LU1861558580.USD","LU1861559042.SGD"],"gpt_icon":0},{"id":"2486856680","title":"Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2486856680","media":"GlobeNewswire","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486856680?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:30","pubTimestamp":1732537800,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass, Nov.  25, 2024  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2986570/0/en/Intellia-Therapeutics-Announces-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-Nexiguran-Ziclumeran-nex-z-for-the-Treatment-of-Hereditary-Transthyretin-ATTR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4588","IE00B66KJ199.SGD","LU1861559042.SGD","BK4535","AEIS","CRSP","IE00B19Z4B17.USD","BK4585","NTLA","BK4139","BK4157","IE00B7SZL793.SGD","IE0031619046.USD","LU1861558580.USD"],"gpt_icon":0},{"id":"2485673277","title":"Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485673277","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485673277?lang=en_us&edition=fundamental","pubTime":"2024-11-24 17:47","pubTimestamp":1732441620,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics stock has lost nearly half its value since peaking in March.The launch of the company's first drug, Casgevy, has been very slow.Aside from Casgevy, it has five clinical-stage candidates and a lot of cash to develop them.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798604%2Fsmart-investor-studying-stock-charts-getty.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798604%2Fsmart-investor-studying-stock-charts-getty.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/11/24/down-47-since-march-is-crispr-therapeutics-stock-a/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0079474960.USD","LU1861559042.SGD","LU0234570918.USD","BK4532","VERX","LU2324357040.USD","VRTX","LU2462157665.USD","LU1035775433.USD","IE00B19Z3B42.SGD","LU0417517546.SGD","IE0002141913.USD","LU2362541273.HKD","BK4556","IE00B4R5TH58.HKD","LU0061475181.USD","BK4139","LU0823416689.USD","LU1069344957.HKD","IE00BZ9MQY76.HKD","LU0889565916.HKD","LU1093756168.USD","LU2236285917.USD","BK4023","IE00B2B36J28.USD","BK4588","BK4567","LU1093756325.SGD","LENZ","LU1430594728.SGD","LU2362541513.USD","SCD","LU0256863811.USD","IE00BJT1NW94.SGD","LU0289739699.SGD","BK4585","BK4533","LU1861558580.USD","CRSP","LU2362540622.SGD","IE0002270589.USD","IE00BJJMRZ35.SGD","LU0058720904.USD","IE00B19Z9P08.USD","LU0109394709.USD","IE00B19Z9Z06.USD","IE0009355771.USD","IE00B894F039.SGD","LU2456880835.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2485687672","title":"Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485687672","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485687672?lang=en_us&edition=fundamental","pubTime":"2024-11-22 20:30","pubTimestamp":1732278600,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics reported some favorable new clinical trial data.Shares of biotech Intellia Therapeutics  are down by around 33% over the past 30 days, amid the publication of some new data from an early stage clinical trial on Nov. 16 and its third-quarter earnings on Nov. 7.Usually, updates like those two would act as positive catalysts for a stock, assuming there was good news to share.In this case, there wasn't exactly any bad news, but the stock is clearly still smarting from the damage in October, when some clinical results from its gene editing program for hereditary angioedema  didn't stack up very favorably against a competitor's candidate.So is this stock still worth a purchase, or is there a problem that's starting to pick up speed?","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798353%2Fscientist-looks-into-microscope-while-sitting-at-lab-bench.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F798353%2Fscientist-looks-into-microscope-while-sitting-at-lab-bench.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/11/22/down-33-in-1-month-should-you-buy-intellia/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IE00BLDYK493.USD","BK4585","NTLA","BK4139","BK4588","LU1169589451.USD","LU1861558580.USD","BK4198","BK4556","IE00B64QTZ34.USD","HAE","LU0106261612.USD","LU0205194284.USD","LU1169590202.USD","LU0012050646.USD","LU0205193047.USD","LU1861559042.SGD","BK4535"],"gpt_icon":0},{"id":"2485211794","title":"Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485211794","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485211794?lang=en_us&edition=fundamental","pubTime":"2024-11-22 06:15","pubTimestamp":1732227336,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024.In this article, we are going to take a look at where CRISPR Therapeutics AG  stands against the other biotech stocks.Biotechnology Stocks: Navigating Volatility Amid Market Fluctuations and Industry Growth. Contrary to Holz's perspective, 2024 has started off strongly for the biotechnology sector due to a rise in mergers and acquisitions as well as anticipations of falling interest rates. Therefore, estimates suggest that the worldwide biotechnology market might increase at a compound annual growth rate  of around 14% from 2024 to 2033, reaching an astonishing $5.7 trillion. The market for agricultural biotechnology is also expected to develop at a 7.9% compound annual growth rate  and reach $232 billion by 2032.“We still see tailwinds for the industry going forward. Smaller-cap names are still targets for acquisitions by bigger biopharma firms, and a wave of acquisitions has continued since late last year, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iUhc0WOtz6GD0fh.a0A.jQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iUhc0WOtz6GD0fh.a0A.jQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-crispr-therapeutics-ag-crsp-221536997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","SQQQ","BK4556","BK4588","MNQmain","QLD","PSQ","LU1861558580.USD","QID","BK4210","BK4159",".IXIC","CAGR","AG","BK4585","NQmain","BK4139","CRSP","TQQQ"],"gpt_icon":1},{"id":"2485731981","title":"Caribou Biosciences to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2485731981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485731981?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:00","pubTimestamp":1732136400,"startTime":"0","endTime":"0","summary":"BERKELEY, Calif., Nov.  20, 2024  (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984749/0/en/Caribou-Biosciences-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU1861558580.USD","CRSP","BK4556","BK4539","CRBU","BK4585","BK4139","BK4588"],"gpt_icon":0},{"id":"2484744112","title":"Sangamo Therapeutics Shares up 3.3% After FDA Clears Application to Start Trial for Pain Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2484744112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484744112?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:33","pubTimestamp":1732113192,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR12I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","BK4556","BK4139"],"gpt_icon":0},{"id":"2485914405","title":"CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485914405","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485914405?lang=en_us&edition=fundamental","pubTime":"2024-11-20 22:21","pubTimestamp":1732112460,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics’ CRSP shares have lost 6.6% in the past two weeks compared with the industry’s 8.4% decline, as seen in the chart below. The stock has underperformed the sector and the S&P 500 index. Shares of the company are also currently trading below its 50-day and 200-day moving averages.Approval for First CRISPR-Based Therapy: A Boon for CRSP Stock. This approval was a breakthrough for medical science, as it was the first for a CRISPR-based gene-editing therapy. Both SCD and TDT indications have a significant unmet medical need. Casgevy has the potential to alleviate blood transfusion requirements for TDT patients and reduce painful and debilitating sickle crises for SCD patients. Per management, the therapy offers a new treatment option to nearly 35,000 patients living with severe SCD or TDT across the United States and Europe, with additional patients in Bahrain and Saudi Arabia.CRISPR Therapeutics is yet to record collaboration revenues from Vertex for Casgevy sales.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-stock-falls-7-142100045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0079474960.USD","LU1069344957.HKD","LU2362541513.USD","LU0889565916.HKD","LU2456880835.USD","LU1035775433.USD","BK4535","IE00B19Z3581.USD","LU1093756325.SGD","BK4588","IE00B4R5TH58.HKD","LU2462157665.USD","VRTX","BK4139","LU2237438978.USD","EDIT","LU0417517546.SGD","BK4532","LU0061475181.USD","BK4505","SLE","IE00B19Z3B42.SGD","BK4077","LU0109394709.USD","IE0002270589.USD","LU1430594728.SGD","LU1585245621.USD","CRSP","LU0289739699.SGD","LU0320765992.SGD","LU1093756168.USD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU1861559042.SGD","IE00BFTCPJ56.SGD","LU2362541273.HKD","LU2236285917.USD","IE00BJJMRZ35.SGD","LENZ","BEAM","SCD","LU0256863811.USD","BK4585","BK4567","LU2417539215.USD","IE00B19Z9P08.USD","LU0058720904.USD","BK4533","IE0009355771.USD","BK4556"],"gpt_icon":0},{"id":"2484195038","title":"BUZZ-Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2484195038","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484195038?lang=en_us&edition=fundamental","pubTime":"2024-11-20 18:55","pubTimestamp":1732100123,"startTime":"0","endTime":"0","summary":"BUZZ-Sangamo Therapeutics rises after FDA clears application to start trial for pain treatment** Shares of genomic medicine company Sangamo Therapeutics SGMO.O rise 12.24% to $2.20 premarket** Co says U.S. Food and Drug Administration has cleared co's application to start human trial for ST-503** SGMO plans to initiate enrollment of patients in the early-to-mid stage study for ST-503 in mid-2025** The therapy ST-503 is being studied for the treatment of intractable pain due to idiopathic small fiber neuropathy , a type of chronic nerve pain** Up to last close, stock had more than tripled YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR0OO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4556","BK4139"],"gpt_icon":0},{"id":"2484195669","title":"Sangamo Therapeutics Shares up 12.2% Premarket After FDA Clears Application to Start Trial for Pain Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2484195669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484195669?lang=en_us&edition=fundamental","pubTime":"2024-11-20 18:49","pubTimestamp":1732099793,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nFWN3MR0ER:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","BK4556","BK4139"],"gpt_icon":0},{"id":"2484118286","title":"Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2484118286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484118286?lang=en_us&edition=fundamental","pubTime":"2024-11-20 09:15","pubTimestamp":1732065307,"startTime":"0","endTime":"0","summary":"20:12 EST Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-223-5k-shares-of-intellia-therapeutics-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-223-5k-shares-of-intellia-therapeutics-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKK","BK4544","BK4556","NTLA","LU1861559042.SGD","BK4585","BK4139","LU1861558580.USD","BK4535","BK4588"],"gpt_icon":0},{"id":"2484185725","title":"CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2484185725","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484185725?lang=en_us&edition=fundamental","pubTime":"2024-11-20 08:03","pubTimestamp":1732061024,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now.In this article, we are going to take a look at where CRISPR Therapeutics AG  stands against the other genomics stocks.Genomics is the study of genes and how they function. Many rapidly growing companies are emerging in the genomics field as technological advances substantially reduce the cost, accuracy, and time required to map a human being's genome.The fields of gene editing and cell and gene therapies  are also developing quickly. The UK approved Casgevy for sickle cell disease and β-thalassemia, pointing out the potential of CRISPR gene editing. According to Deloitte’s research report, the growing market for CGTs, from US$5.3 billion in 2022 to $19.9 billion in 2027, signals a shift towards customized advanced medicine despite high costs leading innovative business models. Furthermore, as per th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iUhc0WOtz6GD0fh.a0A.jQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iUhc0WOtz6GD0fh.a0A.jQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-among-000344479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","QID","SQQQ","NQmain","BK4556","MNQmain","TQQQ","BK4585","CRSP","LU1861558580.USD","QLD","BK4139","BK4210",".IXIC","BK4588","ARKK","BK4544","AG","LU1861559042.SGD"],"gpt_icon":1},{"id":"2484901071","title":"BRIEF-Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503","url":"https://stock-news.laohu8.com/highlight/detail?id=2484901071","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484901071?lang=en_us&edition=fundamental","pubTime":"2024-11-20 06:14","pubTimestamp":1732054486,"startTime":"0","endTime":"0","summary":"Nov 19  - Sangamo Therapeutics Inc   :   * SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL FIBER NEUROPATHY, A TYPE OF CHRONIC NEUROPATHIC PAIN   * SANGAMO THERAPEUTICS INC - TO INITIATE PHASE 1/2 STUDY FOR ST-503 IN MID-2025Source text:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LENZ","SGMO","BK4139"],"gpt_icon":0},{"id":"2484890908","title":"Sangamo stock climbs 12% post-market on FDA update for ST-503","url":"https://stock-news.laohu8.com/highlight/detail?id=2484890908","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484890908?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:51","pubTimestamp":1732053102,"startTime":"0","endTime":"0","summary":"Iryna Drozd Shares of Sangamo Therapeutics  rose 12% in post-market trading Tuesday after the company announced the FDA had cleared it to begin clinical testing of its drug candidate ST-503 in the treatment of intractable pain due to idiopathic small fiber neuropathy, or iSFN. The company plans to begin enrolling patients in a Phase 1/2 study for ST-503 for the indication in mid-2025, according to a statement. Sangamo  said if the study is successful, development of ST-503 could be broadened to other types of chronic neuropathic pain.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1387472103/image_1387472103.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4309358-sangamo-stock-climbs-post-market-on-fda-update-for-st-503","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SGMO","BK4139","BK4556"],"gpt_icon":0},{"id":"2484419906","title":"Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2484419906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484419906?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:41","pubTimestamp":1732052460,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.Shares rise 10%, to $2.14, in after-hours trading Tuesday. Through the close, the stock has more than tripled since the beginning of the year.The genomic-medicine company said it is preparing to initiate enrollment of patients in the phase 1/2 study for the ST-503 program, an investigational epigenetic regulator.Overall, the company plans to initiate patient enrollment in mid-2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4556","SGMO"],"gpt_icon":0},{"id":"2484057489","title":"Sangamo gets FDA clearance of IND application for ST-503 in iSFN","url":"https://stock-news.laohu8.com/highlight/detail?id=2484057489","media":"TIPRANKS","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484057489?lang=en_us&edition=fundamental","pubTime":"2024-11-20 05:20","pubTimestamp":1732051257,"startTime":"0","endTime":"0","summary":"The company states: “Sangamo (SGMO) Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sangamo-gets-fda-clearance-of-ind-application-for-st-503-in-isfn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sangamo-gets-fda-clearance-of-ind-application-for-st-503-in-isfn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","SGMO","BK4139"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}